ERBB2 and breast cancer: Blocking human epidermal growth factor receptor 2 (HER 3) signaling using antibodies (such as trastuzumab, pertuzumab, and trastuzumab-emtasine) has improved outcomes for patients with HER2-positive breast cancer when combined with chemotherapy.